Predicting individual responses to pravastatin using a physiologically based kinetic model for plasma cholesterol concentrations
- 320 Downloads
We used a previously developed physiologically based kinetic (PBK) model to analyze the effect of individual variations in metabolism and transport of cholesterol on pravastatin response. The PBK model is based on kinetic expressions for 21 reactions that interconnect eight different body cholesterol pools including plasma HDL and non-HDL cholesterol. A pravastatin pharmacokinetic model was constructed and the simulated hepatic pravastatin concentration was used to modulate the reaction rate constant of hepatic free cholesterol synthesis in the PBK model. The integrated model was then used to predict plasma cholesterol concentrations as a function of pravastatin dose. Predicted versus observed values at 40 mg/d pravastatin were 15 versus 22 % reduction of total plasma cholesterol, and 10 versus 5.6 % increase of HDL cholesterol. A population of 7,609 virtual subjects was generated using a Monte Carlo approach, and the response to a 40 mg/d pravastatin dose was simulated for each subject. Linear regression analysis of the pravastatin response in this virtual population showed that hepatic and peripheral cholesterol synthesis had the largest regression coefficients for the non-HDL-C response. However, the modeling also showed that these processes alone did not suffice to predict non-HDL-C response to pravastatin, contradicting the hypothesis that people with high cholesterol synthesis rates are good statin responders. In conclusion, we have developed a PBK model that is able to accurately describe the effect of pravastatin treatment on plasma cholesterol concentrations and can be used to provide insight in the mechanisms behind individual variation in statin response.
KeywordsPersonalized medicine Virtual subjects LDL Cholesterol Statin response PBK modeling
High density lipoprotein
- HMG-CoA reductase
Low density lipoprotein
Physiologically based kinetic
Total plasma cholesterol
Very low density lipoprotein
We thank Sieto Bosgra for assistance with the pravastatin PBPK model.
Conflict of interest
The authors declare no conflict of interest.
- 6.Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670–1681PubMedCrossRefGoogle Scholar
- 10.Pearson TA, Laurora I, Chu H, Kafonek S (2000) The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160:459–467PubMedCrossRefGoogle Scholar
- 21.MathWorks (2007). MATLAB (www.mathworks.com/products/matlab/)
- 22.Petrie A, Sabin C (2009) Medical Statistics at a Glance. Wiley-Blackwell, LondonGoogle Scholar
- 39.Matthan NR, Resteghini N, Robertson M, Ford I, Shepherd J, Packard C, Buckley BM, Jukema JW, Lichtenstein AH, Schaefer EJ (2010) Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial. J Lipid Res 51:202–209PubMedCentralPubMedCrossRefGoogle Scholar